VACC Vaccitech plc

14.9
-0.17  -1%
Previous Close 15.07
Open 14.77
52 Week Low 12.25
52 Week High 17.99
Market Cap $511,490,642
Shares 34,328,231
Float 32,899,041
Enterprise Value $345,517,043
Volume 10,092
Av. Daily Volume 33,199
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
VTP-300 (HBV001)
Hepatitis B and healthy volunteers
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
VTP-300 (HBV002)
Hepatitis B
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
VTP-200
Human papillomavirus (HPV)
Phase 1/2
Phase 1/2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
AB-729 and VTP-300
Hepatitis B
Phase 2a
Phase 2a
Phase 2 trial to be initiated 2H 2021.
VTP-600 and KEYTRUDA (pembrolizumab)
Non-small cell lung cancer
Phase 1/2
Phase 1/2
Phase 1/2 trial to commence 3Q 2021.
VTP-400
Shingles
Phase 1
Phase 1
Phase 1 trial to to commence 1H 2022.
VTP-850
Prostate cancer
Phase 1/2
Phase 1/2
Phase 1/2 trial to commence 1Q 2022.
AZD1222
COVID-19 vaccine
Phase 3
Phase 3
Phase 3 data exhibited 70% efficacy (90% and 60% across two dosing regimens) - UK and Brazil trial. Data from U.S. trial noted 76% efficacy rate - March 24, 2021.

Latest News

  1. OXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company's Chief Executive Officer, Bill Enright, will be presenting at the William Blair Biotech Focus Conference 2021 on Thursday, July 15 at 1 p.m. EDT.

    A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

    About Vaccitech plc
    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development…

    OXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company's Chief Executive Officer, Bill Enright, will be presenting at the William Blair Biotech Focus Conference 2021 on Thursday, July 15 at 1 p.m. EDT.

    A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

    About Vaccitech plc

    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

    Vaccitech Media contacts:

    Katja Stout, Scius Communications (EU)

    Direct: +44 (0) 7789435990

    Email:

    Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

    212-213-0006 ext. 315 / 364

    Email:  /

    Henry Hodge, Vaccitech

    Email:



    Primary Logo

    View Full Article Hide Full Article
  2. WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) and Vaccitech plc (NASDAQ:VACC) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus (HBV) infection (CHB) who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy.

    The multi-center, Phase 2a clinical trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutus's proprietary GalNAc delivered RNAi therapeutic, AB-729, followed by Vaccitech's proprietary immunotherapeutic, VTP-300, in NrtI-suppressed…

    WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) and Vaccitech plc (NASDAQ:VACC) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus (HBV) infection (CHB) who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy.

    The multi-center, Phase 2a clinical trial will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of Arbutus's proprietary GalNAc delivered RNAi therapeutic, AB-729, followed by Vaccitech's proprietary immunotherapeutic, VTP-300, in NrtI-suppressed subjects with CHB. The Phase 2a clinical trial is expected to initiate in the second half of this year and will be managed by Arbutus, subject to oversight by a joint development committee comprised of representatives from Arbutus and Vaccitech. The parties retain full rights to their respective product candidates and will split all costs associated with the clinical trial. Pursuant to the agreement, the parties intend to undertake a larger Phase 2b clinical trial depending on the results of the initial Phase 2a clinical trial.

    "Based on the positive clinical results we have seen in our ongoing Phase 1a/1b clinical trial for AB-729, including recent data demonstrating increased HBV-specific immune responses, we believe AB-729 has the potential to become a cornerstone therapeutic in multiple future HBV combination regimens," stated Gaston Picchio, Chief Development Officer at Arbutus. "We are looking forward to initiating this proof-of-concept Phase 2a clinical trial, which will allow us to evaluate the combination of two promising clinical candidates with potential complimentary mechanisms of action. We believe combining AB-729, which is designed to reduce HBsAg resulting in increased HBV immune responses with VTP-300, an immunotherapeutic designed to elicit an HBV specific immune response, may offer patients with CHB a much needed and durable functional cure."

    "CHB is characterized by T cell exhaustion, driven primarily by HBsAg, that may require immune modulation," said Tom Evans, MD, Vaccitech's Chief Scientific Officer. "Current treatments can control viral replication but do not cure the disease. We believe that a combination of immunotherapy, such as VTP-300, with agents that reduce hepatitis B surface antigen is a promising approach toward a functional cure. This clinical trial will be evaluating that hypothesis. If successful, we believe that VTP-300, along with siRNA, such as AB-729, could be a foundation for CHB combination therapy."

    About the Phase 2a Clinical Trial

    Pending regulatory approval, the trial is expected to enroll 40 NrtI-suppressed, Hepatitis B e-antigen negative or positive, non-cirrhotic CHB subjects. Subjects are expected to receive AB-729 + NrtI for 24 weeks. At Week 24, subjects will be randomized 1:1 to receive either NrtI + VTP-300 or NrtI + VTP-300 sham. At Week 48, all subjects are expected to be evaluated for eligibility to either discontinue all treatments or remain on their NrtI only. Subjects are expected to be followed for an additional 48 weeks.

    About AB-729

    AB-729 is an RNA interference (RNAi) therapeutic targeted to hepatocytes using Arbutus' novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology that enables subcutaneous delivery. AB-729 inhibits viral replication and reduces all HBV antigens, including hepatitis B surface antigen in preclinical models. Reducing hepatitis B surface antigen is thought to be a key prerequisite to enable reawakening of a patient's immune system to respond to the virus. Based upon clinical data generated thus far in an ongoing single- and multi-dose Phase 1a/1b clinical trial, AB-729 has demonstrated positive safety and tolerability data and meaningful reductions in hepatitis B surface antigen.

    About VTP-300

    VTP-300 utilizes Vaccitech's ChAdOx1-HBV/MVA-HBV prime-boost combination to elicit an immune response against HBV. The HBV DNA sequence contained in the viral vectors is derived from a genotype C sequence, which is the most common genotype circulating worldwide. Vaccitech's proprietary platform has demonstrated robust activation of cytotoxic CD8+ T cells (immune cells associated with clearance of HBV infected cells), which are believed to have the potential to lead to a functional cure for patients with CHB, a life-threatening disease that affects more than 250 million people worldwide. VTP-300 is currently being evaluated in ongoing Phase 1/2a clinical trial in healthy volunteers and CHB patients and a Phase 1b/2a clinical trial in CHB patients in combination with a low-dose checkpoint inhibitor.

    About HBV

    Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. CHB represents a significant unmet medical need. The World Health Organization estimates that over 250 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2 million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective prophylactic vaccines and current treatment options.

    About Arbutus

    Arbutus Biopharma Corporation is a publicly traded (NASDAQ:ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.

    About Vaccitech

    Vaccitech plc is a publicly traded (NASDAQ:VACC) clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

    Arbutus Forward-Looking Statements and Information

    This press release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and forward-looking information within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements in this press release include statements about our expectations for the collaboration, including Arbutus' belief that combining the ability of AB-729 to reduce HBsAg with VTP-300, an immunotherapeutic that elicits an HBV specific immune response, may offer patients with chronic hepatitis B a much needed and durable functional cure; the timing and expected trial design of the Phase 2a clinical trial to be initiated by the parties pursuant to the agreement; Arbutus' belief that AB-729 has the potential to become a cornerstone therapeutic in multiple future HBV combination regimens; and the parties' plans for future collaboration clinical trials depending on the results of the initial Phase 2a clinical trial.

    With respect to the forward-looking statements contained in this press release, Arbutus has made numerous assumptions regarding, among other things: the effectiveness and timeliness of preclinical studies and clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the continued demand for Arbutus' assets; and the stability of economic and market conditions. While Arbutus considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies, including uncertainties and contingencies related to the ongoing COVID-19 pandemic.

    Additionally, there are known and unknown risk factors which could cause Arbutus' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the parties may never realize the expected benefits of the collaboration; anticipated clinical trials may be more costly or take longer to complete than anticipated, and may never be initiated or completed, or may not generate results that warrant future development of the candidate; Arbutus may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; market shifts may require a change in strategic focus; and the ongoing COVID-19 pandemic could significantly disrupt clinical development programs.

    A more complete discussion of the risks and uncertainties facing Arbutus appears in Arbutus' Annual Report on Form 10-K, Arbutus' Quarterly Reports on Form 10-Q and Arbutus' continuous and periodic disclosure filings, which are available at www.sedar.com and at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Arbutus disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

    Vaccitech plc Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding risks and uncertainties related to Vaccitech's expectations regarding the benefits of this collaboration, including the potential benefits of using VTP-300 in triple combination with AB-729 and an NrtI, the timing and expected trial design of the Phase 2a clinical trial to be initiated by the parties pursuant to the agreement and Vaccitech's expectations that, if the clinical trial is successful, VTP-300 together with AB-729, could be a foundation for CHB combination therapy. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to timing and advancement of the planned clinical trial and other risks identified in Vaccitech's SEC filings, including its Quarterly Report on Form 10-Q for the first quarter of 2021 and subsequent filings with the SEC. Existing and prospective investors are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Vaccitech expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

    Arbutus Contact Information

    Investors and Media

    William H. Collier

    President and CEO

    Phone: 267-469-0914

    Email:

    Pam Murphy

    Investor Relations Consultant

    Phone: 267-469-0914

    Email:

    Vaccitech Contact Information

    Investors:

    Vaccitech Investor Relations

     

    Media:

    Katja Stout, Scius Communications (EU)

    Direct: +44 (0) 7789435990

    Email: 

    Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

    212-213-0006 ext. 315 / 364

    Email:  / 

    Henry Hodge, Vaccitech

    Email: 



    Primary Logo

    View Full Article Hide Full Article
  3. OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Company's recent corporate developments.

    "The first quarter of 2021 was transformational for Vaccitech as we closed a Series B financing round and initiated patient dosing in our two lead therapeutic programs, HBV and HPV," said Bill Enright, CEO of Vaccitech. "We drove on to successfully complete our IPO early in the second quarter and are now capitalized to advance…

    OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Company's recent corporate developments.

    "The first quarter of 2021 was transformational for Vaccitech as we closed a Series B financing round and initiated patient dosing in our two lead therapeutic programs, HBV and HPV," said Bill Enright, CEO of Vaccitech. "We drove on to successfully complete our IPO early in the second quarter and are now capitalized to advance multiple pipeline candidates into Phase 3 trials."

    First Quarter and Recent Corporate Developments

    • Closed an initial public offering of American Depository Shares for total gross proceeds of $110.5 million
    • Initiated patient dosing in HPV001, a Phase 1/2 clinical trial of VTP-200, an immunotherapeutic in development for the treatment of high-risk and persistent HPV infection
    • Completed a $168 million Series B financing. This includes $43 million of proceeds from previously issued convertible loan notes that converted into Series B shares
    • Appointed three independent members to its Board of Directors
    • Initiated patient dosing in HBV002, a Phase 1b/2a clinical trial of VTP-300, an immunotherapeutic candidate in development for the treatment of chronic HBV infection

    Upcoming Milestones

    • Third quarter of 2021: VTP-300 topline safety and immunogenicity results of the Phase 1 trial, HBV001, in healthy volunteers and patients with chronic HBV infection
    • Third quarter of 2021: VTP-600 dosing initiation in patients with non-small cell lung cancer in combination with a checkpoint inhibitor and chemotherapy
    • Fourth quarter of 2021: VTP-300 interim efficacy review, including surface antigen loss, of HBV002, the Phase 1/2a clinical trial in patients with chronic HBV infection
    • First quarter of 2022: VTP-200 interim efficacy review of HPV100, the Phase 1/2a clinical trial in patients with high-risk and persistent HPV infection

    First Quarter 2021 Financial Highlights:

    • Cash position: As of March 31, 2021, cash and cash equivalents were $155.9 million, compared to $43.3 million as of December 31, 2021. The increase was primarily due to completion of the Series B financing. Subsequent to the end of the first quarter, the Company closed an initial public offering that raised a gross amount of $110.5 million. The Company believes its cash and cash equivalents are sufficient to fund operations into 2024.
    • Research and development (R&D) expenses: Research and development expenses were $4.6 million for the first quarter of 2021 compared to $4.2 million for the comparable period of the prior year. The increase in R&D expense was primarily due to increased spending on progressing VTP-300 and VTP-850 development.
    • General and administrative expenses: General and administrative expenses were $1.8 million for the first quarter of 2021 compared to $1.1 million for the comparable period of the prior year. The increase was primarily attributable to higher personnel costs driven by an increase in the Company's headcount between the quarters and higher professional fees.
    • Other expenses: Other expenses, net were $9.3 million for the first quarter of 2021 compared to $0.7 million of income for the comparable period of the prior year. The increase in other expenses was primarily attributable to loss on extinguishment of convertible loan notes of $13.8 million and interest on loan notes of $2.7 million in the period, net of gain in fair value of derivatives of $6.0 million.
    • Net loss: The company generated a net loss of $15.3 million, or $1.90 per basic and diluted share, for the first quarter of 2021 compared to a net loss of $3.8 million, or $0.49 per basic and diluted share, for the comparable period of the prior year.

    About Vaccitech

    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding risks and uncertainties related to timing and advancement of our therapeutic programs, our expectations regarding the therapeutic benefit of our programs, our ability to efficiently discover and develop product candidates, our ability to obtain and maintain regulatory approval of our product candidates, the implementation of our business model, strategic plans for our business and product candidates, expectations regarding our new directors, and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the first quarter of 2021 and subsequent filings with the SEC. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to timing and advancement of our therapeutic programs, our expectations regarding the therapeutic benefit of our programs, our ability to efficiently discover and develop product candidates, our ability to obtain and maintain regulatory approval of our product candidates, the implementation of our business model, strategic plans for our business and product candidates, expectations regarding our new directors, and other risks identified in our SEC filings, including our Quarterly Report on Form 10-Q for the first quarter of 2021, as amended, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We expressly disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.





    VACCITECH PLC

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)

    (UNAUDITED)

      March 31,

    2021
      December 31,

    2020
    ASSETS       
    Current assets:     
    Cash and cash equivalents$155,935  $43,266 
    Accounts receivable 312   518 
    Research and development incentives receivable 3,691   2,708 
    Prepaid expenses and other current assets 3,427   1,409 
    Total current assets 163,365   47,901 
    Property and equipment, net 1,003   629 
    Right of use assets, net 2,098   2,136 
    Deferred tax assets 25   - 
    Total assets$166,491  $50,666 
          
    LIABILITIES, REDEEMABLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIT       
    Current liabilities:     
    Accounts payable$4,833  $4,667 
    Accrued expenses and other current liabilities 3,273   2,537 
    Deferred revenue 346   245 
    Current portion of lease liability 198   192 
    Total current liabilities 8,650   7,641 
    Convertible loan notes – non current -   44,700 
    Lease liability – non current 1,435   1,472 
    Total liabilities$10,085  $53,813 
    Commitments and contingencies     
    Series A redeemable convertible preferred shares (Series A shares); £0.10 nominal value; 22,065 shares issued and outstanding; (December 31, 2020: issued and outstanding: 22,065)$33,736  $33,765 
    Series B redeemable convertible preferred shares (Series B shares); £0.10 nominal value; 41,378 shares issued and outstanding; (December 31, 2020: issued and outstanding: 0)$175,501  $- 
    Shareholders' deficit:     
    Ordinary shares, £0.000025 nominal value; 8,224,344 shares authorized, issued and outstanding (December 31, 2020: authorized, issued and outstanding: 7,960,458) -   - 
    Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2020:no shares issued or outstanding) 86   - 
    Deferred C shares, £0,000007 nominal value, 8,224,344 shares authorized, issued and outstanding (December 31, 2020: authorized, issued and outstanding: 7,960,458) -   - 
    Additional paid-in capital 22,457   21,660 
    Accumulated deficit (72,988)  (57,720)
    Accumulated other comprehensive loss – foreign currency translation adjustments (2,663)  (1,243)
    Noncontrolling interest 277   391 
    Total shareholders' deficit$(52,831) $(36,912)
    Total liabilities, redeemable convertible preferred shares and shareholders' deficit$166,491  $50,666 





    VACCITECH PLC

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)

    (UNAUDITED)

      Three months ended
      March 31, 2021  March 31, 2020
    License revenue$16  $3 
    Service revenue 21   219 
    Research grants and contracts 178   483 
    Total revenue 215   705 
    Operating expenses     
    Research and development 4,610   4,242 
    General and administrative 1,777   1,112 
    Total operating expenses 6,387   5,354 
    Loss from operations (6,172)  (4,649)
    Other income (expense):     
    Change in fair value of derivatives 5,994   - 
    Unrealized exchange gain on convertible loan notes 209   - 
    Loss on extinguishment of convertible loan notes (13,789)  - 
    Interest income 2   - 
    Interest expense (2,650)  - 
    Research and development incentives 955   698 
    Total other (expense) income (9,279)  698 
    Tax benefit 65   - 
    Net loss (15,386)  (3,951)
    Net loss attributable to noncontrolling interest 118   130 
    Net loss attributable to Vaccitech Plc. shareholders (15,268)  (3,821)
          
    Weighted-average ordinary shares outstanding, basic and diluted 8,057,216   7,816,681 
    Net loss per share attributable to ordinary shareholders, basic and diluted$(1.90) $(0.49)
          
    Net loss$(15,386) $(3,951)
    Other comprehensive loss – foreign currency translation adjustments (1,416)  (683)
    Comprehensive loss (16,802)  (4,634)
    Comprehensive loss attributable to noncontrolling interest 114   148 
    Comprehensive loss attributable to Vaccitech Plc. shareholders$(16,688) $(4,486)



    Investors:

    Vaccitech Investor Relations

    Vaccitech Media Contacts:

    Katja Stout, Scius Communications (EU)

    Direct: +44 (0) 7789435990

    Email:

    Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

    212-213-0006 ext. 315 / 364

    Email: /

    Henry Hodge, Vaccitech

    Email:



    Primary Logo

    View Full Article Hide Full Article
  4. OXFORD, United Kingdom, June 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company's Chief Executive Officer, Bill Enright, will be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3 at 11:00 AM EDT.

    A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

    About Vaccitech plc
    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development…

    OXFORD, United Kingdom, June 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced that the Company's Chief Executive Officer, Bill Enright, will be presenting at the Jefferies Virtual Healthcare Conference on Thursday, June 3 at 11:00 AM EDT.

    A live webcast of the presentation can be accessed through the Events section of the Vaccitech website. Following the live webcast, a replay will be available at the same location.

    About Vaccitech plc

    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

    Vaccitech Media contacts:

    Katja Stout, Scius Communications (EU)

    Direct: +44 (0) 7789435990

    Email:

    Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

    212-213-0006 ext. 315 / 364

    Email: /

    Henry Hodge, Vaccitech

    Direct: +44 (0) 7533 421 442

    Email:



    Primary Logo

    View Full Article Hide Full Article
  5. OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares ("ADSs") representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS. The gross proceeds from the offering were approximately $110.5 million. Vaccitech's ordinary shares began trading on the Nasdaq Global Market in the U.S. under the ticker symbol "VACC" on April 30, 2021. All ADSs sold in the offering were offered…

    OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ:VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the closing of its initial public offering in the United States of 6,500,000 American Depositary Shares ("ADSs") representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS. The gross proceeds from the offering were approximately $110.5 million. Vaccitech's ordinary shares began trading on the Nasdaq Global Market in the U.S. under the ticker symbol "VACC" on April 30, 2021. All ADSs sold in the offering were offered by Vaccitech.

    Morgan Stanley, Jefferies, Barclays and William Blair acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.

    The Registration Statement on Form S-1 relating to the proposed sale of these securities was filed with the U.S. Securities and Exchange Commission and was declared effective on April 29, 2021.

    The offering of ADSs was made only by means of a prospectus, copies of which may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at ; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at ; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at  or telephone at 1-888-603-5847; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at 

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Vaccitech plc

    Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company's proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

    Vaccitech Media contacts:

    Katja Stout, Scius Communications (EU)

    Direct: +44 (0) 7789435990

    Email: 

    Ryo Imai / Robert Flamm, Ph.D. (US), Burns McClellan, Inc.

    212-213-0006 ext. 315 / 364

    Email: 

    Henry Hodge, Vaccitech

    Direct: +44 (0) 7533 421 442

    Email: 



    Primary Logo

    View Full Article Hide Full Article
View All Vaccitech plc News